Clinical trial
A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy…
NCT00139334 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00139334 |
|---|---|
| Title | A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh |
| Official title | Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Rotavirus |
| Enrollment | 300 |
| Start date | Jun 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Aug 31, 2005 |
| Last update posted | Sep 21, 2016 |
| Countries | Bangladesh |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: